FDA Approves Ivosidenib for Bile Duct Cancer FDA Approves Ivosidenib for Bile Duct Cancer

Ivosidenib is the first targeted therapy approved for the treatment of IDH1-mutated cholangiocarcinomaFDA Approvals
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Alert Source Type: news